Provided herein are antibodies that target tumors, wherein the binding of the antibody to the tumor is dependent on the expression of one or more glycosyltransferases in the tumor. These antibodies bind preferentially to tumor tissue as compared to normal tissue. Such antibodies are used in methods of inhibiting tumor cell growth.
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention provides salts represented by the structure of Formula (I): wherein Q is an ammonium cation; and processes comprising the use of the salts in the preparation of benzodiazepinone compounds, especially bis(fluoroalkyl) derivatives thereof.
The present invention provides salts represented by the structure of Formula (I): wherein Q is an ammonium cation; and processes comprising the use of the salts in the preparation of benzodiazepinone compounds, especially bis(fluoroalkyl) derivatives thereof.
C07D 243/26 - Preparation from compounds already containing the benzodiazepine skeleton
C07C 67/317 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groupsPreparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by hydrogenolysis of functional groups
C07C 69/63 - Halogen-containing esters of saturated acids
C07C 209/68 - Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer. Formula (I)
Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer. Formula (I)
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention provides methods of preparing compound of Formula (I), wherein the compounds are represented by the structure of Formula (I):
The present invention provides methods of preparing compound of Formula (I), wherein the compounds are represented by the structure of Formula (I):
The present invention provides methods of preparing compound of Formula (I), wherein the compounds are represented by the structure of Formula (I):
wherein:
R1 each is independently F, Cl, Br, I, OCH3, CN or NO2;
R2 each is independently identical or different C1-C5 alkyl;
n1 is an integer between 1 and 5; and
n2 is an integer between 1 and 4.
In addition, the present invention provides a compound represented by the following structures:
The present invention provides methods of preparing compound of Formula (I), wherein the compounds are represented by the structure of Formula (I):
wherein:
R1 each is independently F, Cl, Br, I, OCH3, CN or NO2;
R2 each is independently identical or different C1-C5 alkyl;
n1 is an integer between 1 and 5; and
n2 is an integer between 1 and 4.
In addition, the present invention provides a compound represented by the following structures:
The present invention provides methods of preparing compound of Formula (I), wherein the compounds are represented by the structure of Formula (I):
wherein:
R1 each is independently F, Cl, Br, I, OCH3, CN or NO2;
R2 each is independently identical or different C1-C5 alkyl;
n1 is an integer between 1 and 5; and
n2 is an integer between 1 and 4.
In addition, the present invention provides a compound represented by the following structures:
wherein X comprises:
chloride, acetate, adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydroiodide, maleate, 2-hydroxyethanesulfonate, lactate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, sulfonate, tartrate, thiocyanate, toluenesulfonate, or undecanoate salt, or any combination thereof.
Provided herein immunoconjugate comprising an antibody that binds to ephrin receptor A2 (EphA2) and a cytotoxic agent. The cytotoxic agent is an auristatin analogue, and the antibody is conjugated to the auristatin analogue. These immunoconjugates comprising EphA2 antibodies bind preferentially to tumor tissue compared to normal tissue, and they can be used in methods of inducing an immune response and methods of inhibiting tumor cell growth.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 9/00 - Medicinal preparations characterised by special physical form
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
8.
COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF
The present disclosure provides, in certain embodiments, compounds chelated or covalently bound to therapeutic or diagnostic radionuclides, such as a chelated or covalently bound complex of Formula (I) as described herein and their methods of use in the treatment of a disease (e.g., a disease described herein) or imaging.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07K 5/078 - Dipeptides the first amino acid being heterocyclic, e.g. Pro, His, Trp
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations and substances for the treatment
of oncological related diseases and disorders. Biotechnology services, namely, development of monoclonal
antibodies and antibody drug conjugates; pharmaceutical,
medical, scientific, biopharmaceutical and biotechnology
research and development; drug discovery services; providing
medical and scientific research information in the field of
medicine and pharmaceuticals.
Provided herein are antibodies that target tumors. These antibodies bind preferentially to tumor tissue as compared to normal tissue. Such antibodies are used in methods of inhibiting tumor cell growth.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Pharmaceutical preparations and substances for the treatment of oncological related diseases and disorders. (1) Biotechnology services, namely, development of monoclonal antibodies and antibody drug conjugates; pharmaceutical, medical, scientific, biopharmaceutical and biotechnology research and development; drug discovery services; providing medical and scientific research information in the field of medicine and pharmaceuticals.
Provided herein are EphA2 antibodies. These EphA2 antibodies bind preferentially to tumor tissue than normal tissue and bind to EphA2. Such antibodies are used in methods of inducing an immune response and methods of inhibiting tumor cell growth. Additionally provided are methods of producing such antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
Ab-[S-L1-L2-L3-L4-L5-L6-L7-D]n (I)
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
Ab-[S-L1-L2-L3-L4-L5-L6-L7-D]n (I)
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations and substances for the treatment of oncological related diseases and disorders Biotechnology services, namely, development of monoclonal antibodies and antibody drug conjugates; pharmaceutical, medical, scientific, biopharmaceutical and biotechnology research and development; drug discovery services; providing medical and scientific research information in the field of medicine and pharmaceuticals
26.
COMBINATION OF IMMUNOTHERAPEUTICS AND BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR TREATING CANCER
The present invention provides methods of use for compositions comprising an immunotherapeutic such as chimeric antigen receptor T cells (CAR-T cells), and specifically those that target a tumor antigen cleaved by gamma secretase, in combination with bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof;
The present invention provides methods of use for compositions comprising an immunotherapeutic such as chimeric antigen receptor T cells (CAR-T cells), and specifically those that target a tumor antigen cleaved by gamma secretase, in combination with bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof;
The present invention provides methods of use for compositions comprising an immunotherapeutic such as chimeric antigen receptor T cells (CAR-T cells), and specifically those that target a tumor antigen cleaved by gamma secretase, in combination with bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof;
for treating lymphomas.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention provides compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof in combination with a composition comprising one or more B-cell leukemia/lymphoma-2 (Bcl-2) family inhibitors. The present invention also provides methods of treating, suppressing, or inhibiting a hyperproliferative disorder or inhibiting tumor growth in subjects by administering compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof and a second composition comprising one or more Bcl-2 family inhibitors.
This invention relates to antibodies specific for human interleukin-38 (IL-38), including isolated antibodies, or antigen-binding fragments thereof. The antibodies, or antigen-binding fragments thereof, described herm partially or fully block, inhibit, or neutralize a biological activity of IL 38. Methods described herm relate to inhibiting tumor growth or metastasis in an individual afflicted by tumor growth and/or metastasis.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
31.
ANTIBODY COCKTAIL AGAINST SARS-COV-2 SPIKE PROTEIN
Provided herein are antibodies that are useful for treating SARS-CoV-2 infections in a subject. Also provided herein are compositions comprising one or more antibodies, methods of treatment comprising administering one or more antibodies, and kits comprising one or more antibodies.
The present invention provides methods of treating or suppressing Adenoid Cystic Carcinoma (ACC) or inhibiting ACC tumor growth in subjects by administering compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (III) or prodrugs thereof.
This invention relates to treating cancer by targeting the cell membrane-localized adaptor protein, Epsin-1 (EPN1), in combination with targeting one or more immune checkpoint proteins, including targeting programmed cell death-ligand 1 (PD-L1) and/or targeting Programmed cell death protein 1 (PD-1)
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
36.
Methods of preparing chiral benzodiazepinone derivatives
Provided herein are methods for administering antibodies to treat SARS-CoV-2 infections in a subject. Also provided herein are compositions comprising one or more antibodies, methods of treatment comprising administering one or more antibodies, and kits comprising one or more antibodies.
This invention relates to antibodies specific for human interleukin-38 (IL-38), including isolated antibodies, or antigen-binding fragments thereof. The antibodies, or antigen-binding fragments thereof, described here partially or fully block, inhibit, or neutralize a biological activity of IL 38. Methods described here relate to inhibiting tumor growth or metastasis in an individual afflicted by tumor growth and/or metastasis.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Provided herein are EphA2 antibodies. These EphA2 antibodies bind preferentially to tumor tissue than normal tissue and bind to EphA2. Such antibodies are used in methods of inducing an immune response and methods of inhibiting tumor cell growth. Additionally provided are methods of producing such antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
This invention relates to antibodies specific for human interleukin-38 (IL-38), including isolated antibodies, or antigen-binding fragments thereof. The antibodies, or antigen-binding fragments thereof, described here partially or fully block, inhibit, or neutralize a biological activity of IL 38. Methods described here relate to inhibiting tumor growth or metastasis in an individual afflicted by tumor growth and/or metastasis.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention provides methods of reducing tumor size, suppressing or inhibiting tumor growth, or prolonging progression-free survival or overall survival in subjects having Notch-activated breast cancer by administering compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (III): or prodrugs thereof, alone or in combination with a composition comprising a cytotoxic agent. Notch-activated breast cancer may be determined by a) Notch-activating genetic alterations in one or more Notch genes, b) overexpression of one or more Notch-regulated genes, c) overexpression of one or more Notch proteins or Notch-regulated proteins, or a combination thereof.
The present invention provides methods of reducing tumor size, suppressing or inhibiting tumor growth, or prolonging progression-free survival or overall survival in subjects having Notch-activated breast cancer by administering compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (III): or prodrugs thereof, alone or in combination with a composition comprising a cytotoxic agent. Notch-activated breast cancer may be determined by a) Notch-activating genetic alterations in one or more Notch genes, b) overexpression of one or more Notch-regulated genes, c) overexpression of one or more Notch proteins or Notch-regulated proteins, or a combination thereof.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
Provided herein are antibodies that are useful for treating SARS-CoV-2 infections in a subject. Also provided herein are compositions comprising one or more antibodies, methods of treatment comprising administering one or more antibodies, and kits comprising one or more antibodies.
Provided herein are antibodies that are useful for treating SARS-CoV-2 infections in a subject. Also provided herein are compositions comprising one or more antibodies, methods of treatment comprising administering one or more antibodies, and kits comprising one or more antibodies.
This invention relates to antibodies specific for members of the human Sorting nexin-9 (SNX9), SNX9 subfamily of Sorting nexin proteins, including SNX18 and SNX33. Antibodies of the invention may be characterized as having complementary determining region (CDR) loops H1, H2, H3, L1, L2, and L3, wherein: the H1 loop amino acid sequence comprises SEQ ID NO: 15; the H2 loop amino acid sequence comprises SEQ ID NO: 16; the H3 loop amino acid sequence comprises SEQ ID NO: 17; the L1 loop amino acid sequence comprises SEQ ID NO: 18; the L2 loop amino acid sequence comprises SEQ ID NO: 19; and the L3 loop amino acid sequence comprises SEQ ID NO: 20. The antibodies are characterized by relatively enhanced internalization by SNX9 subfamily-expressing tumor cells, as well as by enhanced binding at the surface of tumor cells in the presence of SNX9, SNX18, or SNX33 in the tumor microenvironment.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
Described herein, are antibodies specific for epsin-1 (EPN1), an antigen expressed on the surface of various cancer cells. Methods for treating, ameliorating and diagnosing various types of cancers characterized by EPN1-expressing tumor cells are also disclosed.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present invention provides compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof; (I), in combination with an ani-CD20 agent or other anti-CD20 therapy, and methods of use thereof for treating diseases and disorders such as cancer.
The present invention provides compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof; (I), in combination with an ani-CD20 agent or other anti-CD20 therapy, and methods of use thereof for treating diseases and disorders such as cancer.
The inventions described herein are directed to bispecific antibodies that are capable of selectively targeting exosomes by specifically binding a first exosome-associated protein and Programmed Death Ligand-1 (“PD-L1”) as a second exosome-associated protein. These bispecific antibodies can disrupt the suppression of anti-tumor activity by immune cells by targeting tumor-cell derived exosomes that inhibit T cell activation. Therefore, bispecific antibodies of the invention can be used in methods for treating cancers.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
48.
COMBINATION COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THEREOF
The present invention provides compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof; in combination with an additional cancer therapeutic agent, and methods of use thereof for treating diseases and disorders such as cancer.
The present invention provides compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof; in combination with an additional cancer therapeutic agent, and methods of use thereof for treating diseases and disorders such as cancer.
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
This invention relates to the incorporation of one, or more, heterologous antibody epitopes into the AB, EF, or CD structural loops of the constant heavy domain 3 (“CH3 domain”) of an engineered antibody or Fc-linked therapeutic agent. The heterologous epitopes serve as “epitope tags” that are specifically detectable by epitope tag-specific detector antibodies, irrespective of the tagged agent's target specificity. Therefore, the epitope tags are useful for the rapid detection of any tagged antibody or Fc-linked agent in biological samples, including samples, which also contain endogenous antibodies.
The present invention provides methods of use for compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof; for treating diseases and disorders such as cancer.
The present invention provides methods of use for compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof; for treating diseases and disorders such as cancer.
The present invention provides compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof;
in combination with an additional cancer therapeutic agent, and methods of use thereof for treating diseases and disorders such as cancer.
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
This invention relates to antibodies specific for human interleukin-38 (IL-38), including isolated antibodies, or antigen-binding fragments thereof. The antibodies, or antigen-binding fragments thereof, described here partially or fully block, inhibit, or neutralize a biological activity of IL 38. Methods described here relate to inhibiting tumor growth or metastasis in an individual afflicted by tumor growth and/or metastasis.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The inventions described herein are directed to bispecific antibodies that are capable of selectively targeting exosomes by specifically binding a first exosome-associated protein and Programmed Death Ligand-1 ("PD-L1") as a second exosome-associated protein. These bispecific antibodies can disrupt the suppression of anti-tumor activity by immune cells by targeting tumor-cell derived exosomes that inhibit T cell activation. Therefore, bispecific antibodies of the invention can be used in methods for treating cancers.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Described herein, are antibodies specific for epsin-1 (EPN1), an antigen expressed on the surface of various cancer cells. Methods for treating, ameliorating and diagnosing various types of cancers characterized by EPN1-expressing tumor cells are also disclosed.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
55.
Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating Adenoid Cystic Carcinoma
The present invention provides methods of treating or suppressing Adenoid Cystic Carcinoma (ACC) or inhibiting ACC tumor growth in subjects by administering compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (III) or prodrugs thereof.
This invention relates to the incorporation of one, or more, heterologous antibody epitopes into the AB, EF, or CD structural loops of the constant heavy domain 3 ("CH3 domain") of an engineered antibody or Fc-linked therapeutic agent. The heterologous epitopes serve as "epitope tags" that are specifically detectable by epitope tag-specific detector antibodies, irrespective of the tagged agent's target specificity. Therefore, the epitope tags are useful for the rapid detection of any tagged antibody or Fc- linked agent in biological samples, including samples, which also contain endogenous antibodies.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Monoclonal antibodies for medical and scientific research; antibodies and immunoconjugates for medical and scientific research; proteins and components of proteins for medical and scientific research; cells, cell extracts and components of cells for medical and scientific research.
(2) Monoclonal antibodies and immunoconjugates for medical or clinical use; pharmaceutical compositions comprising monoclonal antibodies for use in the diagnosis, prevention, management and treatment of oncological, neurological, infectious disease, metabolic, viral, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, hepatological, opthalmic, respiratory, gastrointestinal, hormonal, dermatological, psychiatric and immune system related conditions, diseases and disorders; pharmaceutical compositions comprising immunoconjugates in the diagnosis, prevention, management and treatment of oncological, neurological, infectious disease, metabolic, viral, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, hepatological, opthalmic, respiratory, gastrointestinal, hormonal, dermatological, psychiatric and immune system related conditions, diseases and disorders; cells, cell extracts and components of cells for medical or clinical use; pharmaceutical preparations for use in the diagnosis, prevention, management and treatment of oncological, neurological, infectious disease, metabolic, viral, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, hepatological, opthalmic, respiratory, gastrointestinal, hormonal, dermatological, psychiatric and immune system related conditions, diseases and disorders; diagnostic preparations for medical use; diagnostic kits comprising reagents for medical and clinical use (1) Biotechnology services, namely, development of monoclonal antibodies; pharmaceutical, medical, scientific, biopharmaceutical and biotechnology research and development; drug discovery services; providing medical and scientific research information in the field of medicine and pharmaceuticals
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Monoclonal antibodies for medical and scientific research; antibodies and immunoconjugates for medical and scientific research; proteins and components of proteins for medical and scientific research; cells, cell extracts and components of cells for medical and scientific research. Monoclonal antibodies and immunoconjugates for medical or clinical use; pharmaceutical compositions comprising monoclonal antibodies for use in the diagnosis, prevention, management and treatment of oncological, neurological, infectious disease, metabolic, viral, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, hepatological, opthalmic, respiratory, gastrointestinal, hormonal, dermatological, psychiatric and immune system related conditions, diseases and disorders; pharmaceutical compositions comprising immunoconjugates in the diagnosis, prevention, management and treatment of oncological, neurological, infectious disease, metabolic, viral, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, hepatological, opthalmic, respiratory, gastrointestinal, hormonal, dermatological, psychiatric and immune system related conditions, diseases and disorders; cells, cell extracts and components of cells for medical or clinical use; pharmaceutical preparations for use in the diagnosis, prevention, management and treatment of oncological, neurological, infectious disease, metabolic, viral, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, hepatological, opthalmic, respiratory, gastrointestinal, hormonal, dermatological, psychiatric and immune system related conditions, diseases and disorders; diagnostic preparations for medical use; diagnostic kits comprising reagents for medical and clinical use. Biotechnology services, namely, development of monoclonal antibodies; pharmaceutical, medical, scientific, biopharmaceutical and biotechnology research and development; drug discovery services; providing medical and scientific research information in the field of medicine and pharmaceuticals.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Biotechnology services, namely, development of monoclonal antibodies; pharmaceutical, medical, scientific, biopharmaceutical and biotechnology research and development; drug discovery services; providing medical and scientific research information in the field of medicine and pharmaceuticals
